Ambalal Sarabhai Enterprises Ltd (AMBALALSA) — shareholding pattern, promoter holding, financials and share price

About Ambalal Sarabhai Enterprises Ltd (AMBALALSA)

Ambalal Sarabhai Enterprises Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as AMBALALSA and on the BSE under scrip code 500009. Its ISIN is INE432A01017.

Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics [1]

Ambalal Sarabhai Enterprises Ltd. is a pioneering company in pharmaceuticals and electronics manufacturing, operating domestically and internationally.

ASE has a strong historical legacy, entering various technical collaborations and forming joint ventures to enhance its product offerings.

Listed peers in Pharmaceuticals: Lyka Labs Ltd, Aarey Drugs & Pharmaceuticals Ltd, Gennex Laboratories Ltd, Nectar Lifescience Ltd, Kerala Ayurveda Ltd, Coral Laboratories Ltd.

Valuation & Returns

10 Jul 2026

At ₹30.88 a share on 10 Jul 2026, Ambalal Sarabhai Enterprises Ltd (AMBALALSA) was valued at a price-to-earnings ratio of 13.29x against an industry P/E of 36.41x and a price-to-book of 1.49x on a book value of ₹20.66 per share as of Mar 2026. Solomo computes return on equity of 11.24% and return on capital employed of 10.51% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
13.29x
Industry P/E
36.41x
P/B
1.49x
EPS (TTM)
₹2.32
Book value / share
₹20.66
ROE
11.24%
ROCE
10.51%
ROA
6.33%
Debt / equity
0.36x
Dividend yield
0%
EBITDA margin
13.12%
52-week range
₹23.12 – ₹38.85

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Ambalal Sarabhai Enterprises Ltd (AMBALALSA) reported revenue of ₹202 crore, net profit of ₹18 crore and earnings per share of ₹2.32. That compares with revenue of ₹196 crore and net profit of ₹5 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹65.49 crore and net profit ₹6.5 crore (consolidated).

Consolidated annual results for Ambalal Sarabhai Enterprises Ltd (AMBALALSA), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)197170173196202
Net profit (₹ cr)47116518
EPS (₹)6.161.490.740.642.32
Compound annual growth for Ambalal Sarabhai Enterprises Ltd (AMBALALSA). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth11.24%-2.09%3.10%
Profit growth--38.79%261.05%
Stock price CAGR15%0%3%-13%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 31.36% of Ambalal Sarabhai Enterprises Ltd (AMBALALSA) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.01%. Market capitalisation was ₹237 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.

Largest disclosed public shareholders in Jun 2026: HARYANA CONTAINERS LIMITED 2.28%, SHARAD KANAYALAL SHAH 1.46%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202631.36%--0.01%68.64%
Mar 202631.36%--0.01%68.64%
Dec 202531.36%-0.34%0.01%68.64%
Sep 202531.35%-0.34%0.01%68.65%
Jun 202531.35%-0.38%0.01%68.65%
Mar 202531.35%-0.38%0.1%68.65%
Dec 202431.35%--0.1%68.65%
Sep 202431.35%--0.01%68.65%
Every quarter since Mar 2001 Filing data, not investment advice.